drugset / Trial / NCT04897880
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
Phase 2
Terminated
25 enrolled
Australian & New Zealand Children's Haematology/Oncology Group
National Health and Medical Research Council, Australia · collabSecura Bio, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.
Timeline
- Start
- 2019-01-09
- Primary completion
- 2024-05-08
- Completion
- 2024-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 2 mg/m2 | Oral |
| Subject | Panobinostat | Small molecule | 8 mg/m2 | Oral |